Investors might want to bet on LeMaitre Vascular (LMAT) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. Most Powerful Force Impacting Stock Prices As empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. ...

BURLINGTON, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that George W. LeMaitre, Chairman & CEO, will present at the 2024 Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 11:00 AM ET at the Marriott Marquis in New York City. About LeMaitre LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufact ...

Most Powerful Force Impacting Stock Prices LeMaitre Vascular (LMAT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the c ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the quarterly period ended March 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-33092 LEMAITRE VASCULAR, INC. (Exact name of registrant as specified in its charter) Delaware 04-2825458 (State or other jurisdiction of incorporation or organization) FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO ...

Exhibit 99.1 LeMaitre Q1 2024 Financial Results BURLINGTON, MA, May 2, 2024 - LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q1 2024 results, announced a $0.16/share quarterly dividend and provided guidance. Q1 2024 Financial Results On April 30, 2024, the Company's Board of Directors approved a quarterly dividend of $0.16/share of common stock. The dividend will be paid on May 30, 2024, to shareholders of record on May 16, 2024. Share Repurchase Program On Feb ...

BURLINGTON, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its first quarter 2024 financial results on Thursday, May 2, 2024, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the li ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-33092 LEMAITRE VASCULAR, INC. (Exact name of registrant as specified in its charter) Delaware 04-2825458 (State o ...

Exhibit 99.1 LeMaitre Q4 2023 Financial Results BURLINGTON, MA, February 27, 2024 - LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q4 2023 results, announced a $0.16/share quarterly dividend and provided guidance. Q4 2023 Financial Results Bovine patches (+18%), allografts (+52%), valvulotomes (+12%), carotid shunts (+16%) and distributed porcine patches drove Q4 sales. EMEA sales increased 21%, the Americas 20% and APAC 11%. The gross margin increased to 68.1% ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-33092 LEMAITRE VASCULAR, INC. (Exact name of registrant as specified in its charter) Delaware 04-2825458 ...

Financial Data and Key Metrics Changes - Q3 2023 saw a 21% reported sales growth and 16% organic sales growth, with operating income increasing by 49% and EPS rising by 36% [3][16] - Operating expenses grew by 14% in Q3, down from 26% in Q1 and 19% in Q2, indicating improved cost control [3][18] - Gross margin for Q3 was 65%, an increase of 80 basis points year-over-year, driven by price increases and labor productivity improvements [19] Business Line Data and Key Metrics Changes - Bovine patches grew by 22%, valvulotomes by 27%, bovine grafts by 15%, and carotid shunts by 24% in Q3 [9] - Organic sales growth in Q3 was attributed to 11% from price increases and 5% from unit sales [11] Market Data and Key Metrics Changes - Sales growth was reported across all geographies: APAC up 30%, EMEA up 24%, and the Americas up 20% [3] - The company ended Q3 with a record 136 sales representatives, a 15% increase from the previous year [12] Company Strategy and Development Direction - The company is focusing on expanding its international presence, with new offices opened in Bangkok and Madrid, and plans for a French sales office in H1 2024 [13][14] - Regulatory projects include filings for Artegraft and RFA in Europe and XenoSure in China, with expectations for approvals in the next two years [14][15] - The company aims to maintain pricing power in niche markets, benefiting from competitors exiting the market due to regulatory challenges [88] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued sales growth driven by a return to hospital procedures and effective cost management [16][18] - The company anticipates Q4 2023 reported sales growth of 20%, organic sales growth of 16%, and operating income growth of 44% [21][22] Other Important Information - Cash at the end of Q3 2023 was $97 million, an increase of $6.8 million during the quarter [20] - The company has lowered Q4 sales guidance by $1.5 million due to a strengthening dollar and other operational constraints [22] Q&A Session Summary Question: Comments on the M&A environment - Management noted that public multiples have decreased, and they are focusing on disciplined acquisitions in the open vascular market [28] Question: Cash flow from operations in the quarter - Cash flow from operations was reported at $11.8 million for the quarter [36] Question: Impact of GLP-1 drugs on business - Management stated there is no current impact from GLP-1 drugs on their business [52] Question: Competitors leaving the market - Key competitors like Becton Dickinson have exited the shunt market, significantly increasing market share for the company [42] Question: CE mark filing for Artegraft - The CE mark filing for Artegraft is still targeted for submission by December 31 [109] Question: Sales and marketing expenses - Sales and marketing expenses decreased due to seasonal factors and changes in commission structures [101]